MALVERN, Pa., March 31, 2017 /PRNewswire/ -- TELA Bio, Inc., a surgical reconstruction company leading the development and commercialization of OviTex™ Reinforced BioScaffolds (RBSs) for soft tissue repair, announced today that the company will participate in the 16th Annual Needham Healthcare Conference to be held April 4-5, 2017 at the Westin NY Grand Central Hotel in New York City.
Antony Koblish, president and CEO of TELA Bio, will present an overview of the company's OviTex™ portfolio of products for use in hernia repair and abdominal wall reconstruction at 9:40am ET on Wednesday, April 5th.
The Annual Needham Healthcare Conference is a forum for institutional investors and venture capital firms to hear the latest updates from senior management teams of both leading public and private companies in the biotechnology, specialty pharmaceuticals, medical technology & diagnostics and services sectors. For more information visit http://www.needhamco.com/Default/InstitutionalSalesAndTrading/Conferences.aspx.
About TELA Bio, Inc.
TELA Bio, Inc. is a privately-owned company focused on bringing innovative, cost-effective, surgical reconstruction solutions to surgeons, hospitals and patients. The company's OviTex™ Reinforced BioScaffolds (RBSs) products, designed for hernia repair and abdominal wall reconstruction procedures, integrate polymer and biologic materials in a uniquely embroidered construction using novel engineering design principles. The OviTex portfolio is supported by high-quality, data-driven science and extensive pre-clinical research that has consistently demonstrated the advantages of an RBS over commercially available products. OviTex is commercially available in the U.S., and TELA Bio plans to launch OviTex in the European Union. The company is collaborating with leading surgeons to drive rapid product development and establish TELA Bio as a leader in surgical reconstruction. To learn more about TELA Bio visit http://www.telabio.com.
Berry & Company Public Relations
SOURCE TELA Bio, Inc.